On June 5, 2017, Imagion Biosystems Chief Scientist Erika Vreeland, PhD, presented the results of a collaborative tumor detection study to the scientific audience assembled for the international Frontiers in Biomagnetic Particles conference in Asheville, North Carolina. Carried out by researchers from Imagion Biosystems, the University of New Mexico, and Sandia National Laboratories, the study demonstrated the use of superparamagnetic relaxometry (SPMR) for specific detection of HER2 positive tumors in mice. The results suggest the utility of SPMR for sensitive and specific detection of cancer, and represent another successful step in the progression of Imagion Biosystems technology. Download the abstract of Dr. Vreeland’s presentation.
Executive Chairman Bob Proulx on Pitt Street Research’s Stocks Down Under Podcast: Getting ready for a Phase 2 Study
August 21, 2025
Earlier this month, our own Bob Proulx, Executive Chairman of Imagion Biosystems, had the opportunity to join Stuart Roberts on Pitt Street Research’s podcast Stocks